NASDAQ:EPRX Eupraxia Pharmaceuticals Q1 2026 Earnings Results & Report $6.68 -0.64 (-8.74%) Closing price 04:00 PM EasternExtended Trading$6.78 +0.10 (+1.50%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Eupraxia Pharmaceuticals missed analyst earnings expectations in its Q1 2026 results, released May 12, 2026. The company reported EPS of -$0.23 versus the -$0.22 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 12, 2026TimeBefore Market OpensConference Call7:00 AM ET Eupraxia Pharmaceuticals EPS ResultsActual EPS-$0.23Consensus EPS -$0.22Beat/MissMissed by -$0.01One Year Ago EPSN/AEPS Beat Rate2 of last 7 quartersEupraxia Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsEupraxia Pharmaceuticals' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Eupraxia Pharmaceuticals Q1 2026 Earnings FAQ Did Eupraxia Pharmaceuticals beat earnings estimates for Q1 2026? Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported earnings of -$0.23 per share for Q1 2026, missing the consensus estimate of -$0.22. The report was announced on Tuesday, May 12, 2026. When is Eupraxia Pharmaceuticals' next earnings date? Eupraxia Pharmaceuticals' next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Eupraxia Pharmaceuticals on the company's earnings history page. Eupraxia Pharmaceuticals Earnings HeadlinesEupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical ConferencesOctober 9, 2026 | financialpost.comFEupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical ConferencesOctober 9, 2026 | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 13 at 1:00 AM | InvestorPlace (Ad)Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 10.2% - Should You Sell?October 3, 2026 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Eupraxia Pharmaceuticals (NASDAQ:EPRX)October 3, 2026 | americanbankingnews.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Jumps 6.5% - What's Next?October 2, 2026 | americanbankingnews.comSee More Eupraxia Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eupraxia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your email. Email Address About Eupraxia PharmaceuticalsEupraxia Pharmaceuticals (NASDAQ:EPRX) (NASDAQ:EPRX) is a Canadian clinical-stage biotechnology company focused on developing locally delivered therapies designed to treat disease at the site of action while potentially reducing systemic exposure and associated side effects. The company is headquartered in Victoria, British Columbia, and is developing candidates for inflammatory and other serious medical conditions. Eupraxia’s lead program, EP-262, is an extended-release formulation of dexamethasone being developed for the treatment of pain and inflammation associated with osteoarthritis of the knee. The company’s approach is intended to provide sustained drug delivery within the affected joint and is based on its proprietary DiffuSphere technology. The company has also developed EP-7041, an investigational small-molecule inhibitor of factor XIa being evaluated for its potential use in preventing and treating blood clots. Eupraxia does not currently have marketed products and remains focused on research, clinical development and potential commercialization through regulatory approval and strategic partnerships.View Eupraxia Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
